Large Cap · Healthcare · Diagnostics & Research
Large Cap · Healthcare · Diagnostics & Research
Get the AI take on A
Track it to unlock the price chart, verdict and what could change it.
Free to track. No card required.
Overall score
70/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
Free for 3 days, then $9/mo. Cancel anytime.
Lowest
$135
Current price
$154.22
Median target
$159
Highest
$185
Forward P/E
Needs attention · 12% above avg
23.51x
Price / sales
Reasonable · Priced reasonably against its revenue
5.80x
Price / FCF
Rich · Priced far above what its cash flow currently supports
38.59x
EV / EBITDA
Reasonable · Operating earnings make this price a stretch but plausible
21.68x
ROIC
Strong · Comfortably clears the bar for efficient capital use
17.7%
ROE
Favorable · 21.3% - strong capital efficiency
21.3%
Debt / equity
Favorable · 0.47 - strong leverage
0.50x
Current ratio
Strong · Comfortable room to cover bills due within a year
2.10x
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $41.95B | 29.8 | +9.1% | 70 | |
| $11.53B | 22.0 | +19.7% | 78 | |
| $4.60B | 13.9 | +13.5% | 77 | |
| $33.87B | 35.4 | +15.5% | 77 | |
| $1.11T | 40.1 | +49.6% | 76 |
MDT vs. A: Which Stock Should Value Investors Buy Now?
BullishMDT vs. A: Which Stock Should Value Investors Buy Now?
MixedAre Medical Stocks Lagging Adicet Bio (ACET) This Year?
Bullish